Beau R. Webber

TALEN-based gene correction for epidermolysis bullosa.

DNA methylation of Runx1 regulatory regions correlates with transition from primitive to definitive hematopoietic potential in vitro and in vivo.

Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.

Fanconi anemia gene editing by the CRISPR/Cas9 system.

From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.

In Vitro T-Cell Generation From Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination.

Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases.

CRISPR/Cas9 Targeted Gene Editing and Cellular Engineering in Fanconi Anemia.

Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.

CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa.

Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells.

CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells.

Dermatopontin in Bone Marrow Extracellular Matrix Regulates Adherence but Is Dispensable for Murine Hematopoietic Cell Maintenance.

Rapid generation of Col7a1 mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells.

Rapid DNA replication origin licensing protects stem cell pluripotency.

CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression.

Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease.

Highly multiplexed genome engineering using CRISPR/Cas9 gRNA arrays.

EditR: A Method to Quantify Base Editing from Sanger Sequencing.

Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs.

A Genetically Engineered Primary Human Natural Killer Cell Platform for Cancer Immunotherapy.

Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.

Author Correction: Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors.

Efficient targeted integration directed by short homology in zebrafish and mammalian cells.

CRISPR-Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells.

Comparative international incidence of Ewing sarcoma 1988 to 2012.

Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments.

An irradiated marrow niche reveals a small noncollagenous protein mediator of homing, dermatopontin.

MultiEditR: The first tool for the detection and quantification of RNA editing from Sanger sequencing demonstrates comparable fidelity to RNA-seq.

A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers.

Myosin Heavy Chain Converter Domain Mutations Drive Early-Stage Changes in Extracellular Matrix Dynamics in Hypertrophic Cardiomyopathy.

Correction of Fanconi Anemia Mutations Using Digital Genome Engineering.

Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies.

Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade.

A Pan-RNase Inhibitor Enabling CRISPR-mRNA Platforms for Engineering of Primary Human Monocytes.

CRISPR-Cas9 base editors and their current role in human therapeutics.

Germline T cell receptor exchange results in physiological T cell development and function.

Ablation of SYK Kinase from Expanded Primary Human NK Cells via CRISPR/Cas9 Enhances Cytotoxicity and Cytokine Production.

Generation and characterization of an immunodeficient mouse model of mucopolysaccharidosis type II.

Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair.

Precision Enhancement of CAR-NK Cells through Non-Viral Engineering and Highly Multiplexed Base Editing.

Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies.

Development and testing of a versatile genome editing application reporter (V-GEAR) system.

Advancing gene targeting for primary immune deficiencies: Adenine base editing of the human IL2RG locus for correction of SCID-X1.

Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disorders.

Efficient multiplex non-viral engineering and expansion of polyclonal γδ CAR-T cells for immunotherapy.

Ablation of FAS confers allogeneic CD3 CAR T cells with resistance to rejection by T cells and natural killer cells.

CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy.

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial.

Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing.